Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Hi-Tech Pharmacal Loses $4.6M in Fourth Quarter

By Pharmaceutical Processing | July 9, 2013

Shares of Hi-Tech Pharmacal Co. Inc. skidded Tuesday after the generic and branded drugmaker reported a loss of $4.6 million in its fourth quarter as revenue fell and it set aside more than $15 million for a possible investigation settlement.

The Amityville, N.Y., company said its loss amounted to 34 cents per share in the quarter that ended April 30. That compares to $9.9 million, or 73 cents per share, a year ago.

Revenue dropped 5 percent to $58.5 million from $61.3 million a year earlier.

Adjusted earnings totaled 50 cents per share, not counting one-time items, for the most recent quarter.

Analysts expected, on average, earnings of 66 cents per share on $67 million in revenue, according to FactSet.

Hi-Tech said it set aside $15.5 million in the fourth quarter to cover a potential settlement tied to an investigation by the Texas Health and Human Services Commission into the submission of price information.

The company also said its generic pharmaceutical sales fell 7 percent in the quarter to $48.9 million due in part to a drop in selling price for fluticasone propionate nasal spray. Revenue from the company’s branded, over-the-counter products fell 7 percent to $4.9 million.

For the full year, Hi-Tech earned $16.3 million, or $1.19 per share, down from $48.35 million, or $3.59 per share, a year earlier. Revenue rose to $232.4 million from $230 million a year ago.

Its shares fell 7.3 percent, or $2.45, to $31.08 in premarket trading Tuesday. That put the stock down about 9 percent so far this year.

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE